Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study

Taku Kobayashi; Axel Dignass; Xavier Roblin; Yoshie Takatori; Toshihiko Kaise; Alessandra Oortwijn; Corinne Jamoul; Toshifumi Hibi

doi:10.5217/ir.2024.00007

Articles

Page Path: HOME > Intest Res > Volume 23(1); 2025 > Article

Original Article IBD Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study: Taku Kobayashi^1,, Axel Dignass², Xavier Roblin³, Yoshie Takatori⁴, Toshihiko Kaise⁴, Alessandra Oortwijn⁵, Corinne Jamoul⁶, Toshifumi Hibi¹; Intestinal Research 2025;23(1):65-75.
DOI: https://doi.org/10.5217/ir.2024.00007
Published online: June 14, 2024

¹Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

²Department of Medicine I, Agaplesion Markus Hospital, Goethe University, Frankfurt am Main, Germany

³IBD Unit, University Hospital of Saint-Étienne, Saint-Étienne, France

⁴Gilead Sciences K.K., Tokyo, Japan

⁵Galapagos NV, Leiden, Netherlands

⁶Galapagos NV, Mechelen, Belgium

Correspondence to Taku Kobayashi, Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8642, Japan. Tel: +81-3-3444-6161, Fax: +81-3-3448-0553, E-mail: kobataku@insti.kitasato-u.ac.jp

This study was presented to the European Crohn’s and Colitis Organisation (ECCO), Copenhagen, Denmark, March 1-4, 2023.

• Received: January 17, 2024 • Revised: April 4, 2024 • Accepted: April 15, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

2,983 Views
198 Download
1 Web of Science
1 Crossref
1 Scopus

Full Article

Download PDF

Abstract
Graphical abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Supplementary Material
REFERENCES

See letter "In which patients with ulcerative colitis would filgotinib be effective?" in Volume 23 on page 1.

Abstract

Background/Aims
Obtaining and maintaining corticosteroid-free remission are important goals of treatment for ulcerative colitis (UC). Characteristics associated with achieving corticosteroid-free remission were assessed in filgotinib-treated patients in SELECTION, a 58-week, phase 2b/3 trial in moderately to severely active UC.
Methods
This post hoc analysis used data from filgotinib-treated patients receiving corticosteroids at maintenance baseline in SELECTION. Univariate logistic regression was performed to assess induction baseline characteristics associated with 6 months of corticosteroid-free remission at week 58, defined as clinical remission without using corticosteroids for at least 6 months.
Results
At maintenance baseline, 92 and 81 patients were receiving corticosteroids in the filgotinib 200 mg and filgotinib 100 mg groups, respectively. Age, body mass index, history of pancolitis, disease duration, fecal calprotectin levels, C-reactive protein levels, Mayo Clinic Score, concomitant corticosteroids, immunomodulators, and aminosalicylates had no statistically significant effect on the likelihood of achieving corticosteroid-free remission. Baseline characteristics associated with increased odds of corticosteroid-free remission were Mayo Clinic Endoscopic Subscore of 2 (vs. 3) in the filgotinib 200 mg and filgotinib 100 mg groups, and female (vs. male) sex, current (vs. former or never) smoking, and being biologic‑naive (vs. experienced) in the filgotinib 200 mg group.
Conclusions
Steroid tapering can be achieved in patients with UC receiving filgotinib 200 mg independently of baseline characteristics such as clinical activity and duration of illness. However, the likelihood of achieving corticosteroid-free remission was higher among patients who were biologic-naive, current smokers, had low endoscopic inflammatory burden and who were female.
Keywords: Corticosteroids; Filgotinib; Ulcerative colitis

Graphical abstract

INTRODUCTION

Ulcerative colitis (UC) is a chronic, immune-mediated inflammatory bowel disease affecting the rectum and colon and characterized by symptoms of rectal bleeding and diarrhea. The goal of maintenance treatment for UC is to obtain and maintain corticosteroid-free remission, and guidelines recommend against the use of systemic corticosteroids for maintaining remission in patients with UC due to safety concerns [1-3].

Filgotinib is a once daily, oral, Janus kinase 1 (JAK) preferential inhibitor approved in Europe and Japan for the treatment of adults with moderately to severely active UC. Approval of this indication for filgotinib is based on data from the phase 2b/3 SELECTION trial (n = 1,348; 659 biologic-naive, 689 biologic-experienced), which showed filgotinib to be well tolerated and efficacious at inducing and maintaining clinical remission compared with placebo in patients with moderately to severely active UC [4]. At week 58 of SELECTION maintenance, 25 of 92 patients treated with corticosteroids at maintenance baseline had achieved at least 6 months of corticosteroid-free remission with filgotinib 200 mg (the approved dose), compared with 3 of 47 patients in the matched placebo group (P=0.0055) [4]. Subsequent analyses suggested that the corticosteroid-sparing effects of filgotinib 200 mg seen in the SELECTION trial were rapid and sustained, including in patients whose disease was refractory to prior treatments, compared with placebo [5]. Patient characteristics at week 10 (maintenance baseline) that were correlated with corticosteroid-free remission for at least 6 months were: presence of histological remission; endoscopic improvement; lower Mayo Clinic Score; being biologic-naive; and having no previous exposure to, or failure of, tumor necrosis factor antagonists and vedolizumab [5]. Analyses were conducted for the filgotinib 200 mg and filgotinib 100 mg groups combined, and assessed the effects of patient characteristics at week 10 (not at induction baseline) [5]. However, to date, patients’ baseline characteristics before the initiation of treatment with filgotinib that are associated with achieving corticosteroid-free remission with filgotinib have not been assessed.

Physicians take into consideration their patients’ characteristics before initiating treatment and are thus likely to value an assessment of induction baseline characteristics that are associated with achieving corticosteroid-free remission. This post hoc analysis of SELECTION trial data aimed to identify the characteristics at induction baseline that were associated with achieving corticosteroid-free remission for at least 6 months among filgotinib-treated patients who were receiving corticosteroids at maintenance baseline. Results in this post hoc analysis are presented separately for the filgotinib 200 mg and filgotinib 100 mg groups and expand on the number of characteristics evaluated previously, including those without significant association.

METHODS

1. SELECTION Study Design and Participants

SELECTION was a phase 2b/3, double-blind, randomized, placebo-controlled, multicenter trial (NCT02914522) designed to assess the efficacy and safety of filgotinib in the induction and maintenance of remission in patients with moderately to severely active UC. The trial design and inclusion and exclusion criteria have been published previously [4]. Eligible patients were aged 18–75 years and had moderately to severely active UC (total Mayo Clinic Score 6–12; Endoscopy Subscore ≥ 2, Rectal Bleeding Subscore ≥ 1, Stool Frequency Subscore ≥ 1, Physician’s Global Assessment Subscore ≥ 2), with a documented diagnosis of UC for at least 6 months confirmed by endoscopic and histopathological evidence.

The trial comprised two 11-week induction studies (A and B) and a 47-week maintenance study. In the induction studies, patients were randomized in a 2:2:1 ratio to receive filgotinib 100 mg, filgotinib 200 mg, or matched placebo orally once daily for 11 weeks. Patients who were biologic-naive were enrolled in induction study A and those who were biologic-experienced were enrolled in induction study B. Patients with clinical remission or Mayo Clinic Score response at week 10 (maintenance baseline) were considered responders and could enter the maintenance study. The definition of clinical remission was a Mayo Clinic Endoscopy Subscore of 0 or 1, Rectal Bleeding Subscore of 0, and Stool Frequency Subscore of 0 or 1 with a decrease of at least 1 point from induction baseline. Mayo Clinic Score response was defined as a decrease in score of at least 3 points and at least 30% from induction baseline, and a Rectal Bleeding Subscore of 0 or 1 or decrease of at least 1 point from induction baseline. Patients who received filgotinib in induction study A or B were re-randomized in a 2:1 ratio to continue their filgotinib regimen or receive placebo-to-match orally once daily in the maintenance study. Patients who received placebo in the induction studies continued to receive placebo in the maintenance study.

The trial was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines and the Declaration of Helsinki. The study protocol and amendments were reviewed and approved by the Independent Ethics Committee or Institutional Review Board at each study site (Kitasato University Shirokane Institutional Review Board and others). All patients provided written informed consent before study inclusion.

2. Corticosteroid Usage

Patients receiving oral systemic corticosteroid therapy (prednisone ≤ 30 mg/day or budesonide ≤ 9 mg/day) were eligible to enter the SELECTION trial provided that the dose was stable for at least 2 weeks before randomization and for the first 14 weeks after randomization [4]. Corticosteroids were tapered according to a predefined schedule starting at week 14. The rate of steroid reduction was to be between 2.5 mg/wk and 5.0 mg/wk (or equivalent if not prednisone). For patients using budesonide, the budesonide dose was to be reduced by 3 mg every 3 weeks. At the discretion of the treating physician, steroid doses could be increased or restarted at doses up to the baseline dose if symptoms returned. Treatment was considered to have failed if corticosteroid doses were increased to a dose higher than a patient’s baseline dose. Treatment allocation in the induction and maintenance studies was stratified according to baseline corticosteroid use to enable post hoc analyses.

3. Statistical Analysis

This analysis was conducted using data from patients receiving corticosteroids at maintenance baseline. The placebo group sample was too small to conduct any analysis of prognostic factors associated with corticosteroid-free remission. Univariate logistic regression was performed to analyze baseline characteristics associated with 6-month corticosteroid-free remission, defined as achieving clinical remission at week 58 without using corticosteroids to treat UC over a continuous period of at least 6 months. Associations between baseline characteristics and total corticosteroid dose exposure from maintenance baseline were assessed in the filgotinib 200 mg group using univariate linear regression with corticosteroid dose as dependent variable and baseline characteristic as independent variable. P-values were based on the Wald chi-square test using type 3 analysis of effects. P-values of less than 0.05 were considered statistically significant.

RESULTS

1. Participants

In total, 92 patients who received filgotinib 200 mg in the induction and maintenance studies and 81 patients who received filgotinib 100 mg in the induction and maintenance studies were receiving oral systemic corticosteroids at baseline in the maintenance study. All patients in the maintenance study were induction study responders. The 6-month corticosteroid-free remission rate at week 58 among patients treated with corticosteroids at maintenance baseline was 27.2% (25/92) in the filgotinib 200 mg group and 13.6% (11/81) in the filgotinib 100 mg group [4]. Among patients who received placebo during induction and maintenance, 47 were receiving oral systemic corticosteroids at maintenance baseline, of whom only 3 patients (6.4%) achieved at least 6 months of corticosteroid-free remission.

Demographic and clinical characteristics at induction baseline are shown in Table 1 for patients in the filgotinib 200 mg and filgotinib 100 mg groups who were receiving corticosteroids at maintenance baseline. Characteristics are shown overall for each of the filgotinib treatment groups and by presence or absence of corticosteroid-free remission. Of patients receiving corticosteroids at maintenance baseline, 83.7% of those in the filgotinib 200 mg group and 91.4% of those in the filgotinib 100 mg group were taking systemic corticosteroids at induction study baseline. In addition, 22.8% in the filgotinib 200 mg group and 19.8% in the filgotinib 100 mg group were taking concomitant immunomodulators, and 79.3% in the filgotinib 200 mg group and 71.6% in the filgotinib 100 mg group were taking concomitant aminosalicylates.

2. Effects of Baseline Characteristics on Corticosteroid-Free Remission

Among patients who were receiving oral systemic corticosteroids at maintenance baseline, none of the following induction baseline characteristics had statistically significant effects on the likelihood of achieving corticosteroid-free remission for 6 months with filgotinib 200 mg or filgotinib 100 mg: age, body mass index, history of pancolitis, disease duration, fecal calprotectin levels, C-reactive protein levels, Mayo Clinic Score, concomitant corticosteroids, concomitant immunomodulators, and concomitant aminosalicylates (Table 2). A baseline Mayo Clinic Endoscopic Subscore of 2 (vs. 3) was associated with significantly increased odds of corticosteroid-free remission for 6 months in the filgotinib 200 mg and filgotinib 100 mg groups. In the filgotinib 200 mg group only, the odds of achieving corticosteroid-free remission for 6 months were significantly increased in patients who were female, current (vs. former or never) smokers or biologic-naive.

3. Effects of Baseline Characteristics on Corticosteroid Dose Exposure

Table 3 shows the effects of induction baseline characteristics on the mean total corticosteroid dose exposure from maintenance baseline in the filgotinib 200 mg group. Mean (95% confidence interval) and median (interquartile range) total corticosteroid dose exposure from maintenance baseline in the filgotinib 200 mg group by baseline characteristic are listed in Supplementary Table 1. Total mean (95% confidence interval) prednisone-equivalent corticosteroid dose exposure from maintenance baseline to week 58 was 213.7 (161.37 to 266.04) mg in the filgotinib 200 mg group; it was 145.7 (95.09 to 196.31) mg among patients with corticosteroid-free remission and 239.1 (170.01 to 308.15) mg among those with no corticosteroid-free remission.

Most baseline characteristics had no statistically significant effect on corticosteroid dose exposure from maintenance baseline in the filgotinib 200 mg group (Table 3). However, corticosteroid dose exposure from maintenance baseline to week 58 was significantly higher among patients who had never smoked (vs. former or current smokers). Concomitant use of aminosalicylates (vs. nonuse) at baseline was associated with a lower corticosteroid dose exposure from maintenance baseline.

DISCUSSION

An important aim of treatment for UC is to obtain and maintain steroid-free remission [1-3]. Discontinuation of corticosteroids is a core component of comprehensive disease control in UC according to international consensus [6]. In addition, guidelines recommend that courses of oral systemic corticosteroids are used not more than once per year [1-3]. Knowing which baseline characteristics in patients with UC are associated with corticosteroid-free remission is relevant for clinical trial design and disease management in everyday clinical practice. In the SELECTION trial, filgotinib 200 mg (the approved dose) induced clinical remission at week 10 in 26.1% of biologic-naive patients (vs. 15.3% with placebo, P=0.0157) and 11.5% of biologic-experienced patients (vs. 4.2% with placebo, P=0.0103), and maintained clinical remission at week 58 in 37.2% of patients (vs. 11.2% with placebo, P<0.0001) [4]. Among patients receiving filgotinib 100 mg, 23.8% achieved clinical remission at week 58 (vs. 13.5% with placebo, P=0.0420); clinical remission at week 10 was not significantly different between filgotinib 100 mg and placebo [4]. Symptom improvement in the SELECTION trial was rapid, with UC symptoms of rectal bleeding and stool frequency improving within 7 days after treatment initiation with filgotinib 200 mg in both biologic-naive and biologic-experienced patients [7].

At SELECTION trial baseline, 30.7% of biologic-naive patients and 45.7% of biologic-experienced patients were receiving systemic corticosteroids [4]. The current post hoc analysis found that patients with UC who have a Mayo Clinic Endoscopic Subscore of 2 (vs. 3), are female, are current (vs. former or never) smokers, or are biologic-naive may have a higher likelihood of sustained corticosteroid-free remission with filgotinib 200 mg treatment. In addition, corticosteroid dose exposure from maintenance baseline in the filgotinib 200 mg group was lower among those with concomitant use of aminosalicylates (vs. nonuse) and was higher among those who had never smoked (vs. former or current smokers).

The higher likelihood of sustained corticosteroid-free remission in patients with UC who had an induction baseline Mayo Clinic Endoscopic Subscore of 2 (vs. 3) indicates that remission is easier to maintain in patients with less severe disease. In patients treated with infliximab, decreasing week-8 Mayo Clinic Endoscopic Subscores (from 3 to 0) were associated with higher rates of long-term corticosteroid-free symptomatic remission [8]. A previous study showed that long-term maintenance therapy with the JAK inhibitor tofacitinib was more effective in patients who had a baseline Mayo Clinic Endoscopic Subscore of 0 compared with 1 [9]. In addition, a prospective longitudinal cohort study found that the risk of clinical relapse was higher in patients who achieved mucosal healing with a Mayo Clinic Endoscopic Subscore of 1 compared with 0 [10]. Our findings are thus broadly consistent with previous studies indicating poorer long-term treatment outcomes in patients with more severe UC.

Patients in the SELECTION study who were biologic-naive tended to have less severe disease (based on induction baseline Mayo Clinic Score) than patients who were biologic-experienced [11]. The association of biologic-naive (vs. biologic-experienced) status at induction baseline with a higher likelihood of sustained corticosteroid-free remission in our study may thus be driven by lower disease severity in these patients. With regard to the association of female sex with an increased likelihood of maintaining corticosteroid-free remission, numerous sex-based differences in the pathogenesis, epidemiology, clinical course and outcomes of inflammatory bowel disease have been reported previously [12]. Unfortunately, however, our sample size was too small to perform a robust multivariate analysis, and as such we were unable to determine conclusively which of the associations identified in our study were independent.

The lower corticosteroid dose exposure during the maintenance study in current and former (vs. never) smokers and higher likelihood of sustained corticosteroid-free remission in current (vs. former or never) smokers adds to previous studies showing a positive impact of cigarette smoking on disease activity and corticosteroid use in patients with UC (this is in contrast to Crohn’s disease, for which smoking increases the risk of disease and adverse outcomes [13,14]) [15-18]. In patients with UC, smoking dose-dependently reduced the need for corticosteroids and smoking cessation after a UC diagnosis increased the need for corticosteroid treatment [17]. Among patients diagnosed with UC, current smokers were less likely than nonsmokers to be prescribed corticosteroids during a median 9-year follow-up [18]. However, no difference in corticosteroid prescribing rate between smokers and nonsmokers or between persistent smokers and quitters was found in a large cohort study in UC [19]. Transdermal nicotine patches assessed in randomized controlled trials were beneficial for active disease but ineffective as maintenance therapy for UC [20,21]. Smoking cessation is encouraged for general health in patients with UC [3].

The current analysis has important strengths, including using data from a double-blind, randomized, placebo-controlled trial. In total, 173 patients (92 in the filgotinib 200 mg group and 81 in the filgotinib 100 mg group) were receiving corticosteroids at baseline in the maintenance study. A limitation of the current analysis is that it was not prespecified. The small size of the subgroup analysis and the small number of patients who achieved corticosteroid-free remission were also limitations. As a result, we could not perform a robust multivariate analysis to determine independent associations. Patients who did not achieve clinical remission or Mayo Clinic Score response at week 10 in SELECTION were not re-randomized to continue the study. Steroid tapering was protocol specified as of week 14 but was not mandatory. The observed effects on corticosteroid exposure may be a consequence of the study design and should thus be interpreted with caution.

In conclusion, filgotinib treatment enabled achievement of corticosteroid-free remission in patients with UC independently of baseline characteristics or previous therapies. However, the likelihood of achieving corticosteroid-free remission in the filgotinib 200 mg group was higher among patients who were biologic-naive, were current (vs. former or never) smokers, had a lower endoscopic inflammatory burden (Mayo Clinic Endoscopic Subscore of 2 vs. 3) and those who were female. These results could help physicians in clinical practice to develop a treatment strategy for their patients with UC.

NOTES

Funding Source

This study was funded by Gilead Sciences K.K. (Tokyo, Japan), Eisai Co., Ltd. (Tokyo, Japan), and EA Pharma Co., Ltd. (Tokyo, Japan). The SELECTION trial was sponsored by Gilead Sciences Inc. (Foster City, CA, USA). Galapagos NV (Mechelen, Belgium) was a collaborator for the SELECTION trial. Medical writing support was provided by Michael Molloy-Bland PhD of Oxford PharmaGenesis, Melbourne, VIC, Australia and funded by Gilead Sciences K.K. (Tokyo, Japan), Eisai Co., Ltd. (Tokyo, Japan), and EA Pharma Co., Ltd. (Tokyo, Japan).

Conflict of Interest

Kobayashi T has served as an advisory board member, consultant, or speaker for AbbVie, Activaid, Ajinomoto Bio-Pharma, Alfresa Pharma, Alimentiv, Astellas Pharma, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eisai, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceuticals, JIMRO, JMDC, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, Thermo Fisher Scientific and Zeria Pharmaceutical, and has received research funding from AbbVie, Alfresa Pharma, EA Pharma, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Sekisui Medical, Takeda, Thermo Fisher Scientific, and Zeria Pharmaceutical. Dignass A reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis, and endpoint committees from AbbVie, Abivax, Arena Pharmaceuticals, the Falk Foundation, Gilead/ Galapagos, Janssen Pharmaceuticals, and Pfizer; consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb/Celgene, Celltrion, the Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Janssen Pharmaceuticals, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts Pharma, and Vifor Pharma; payment from lectures, including service on speakers bureaus from AbbVie, Biogen, Celltrion, the Falk Foundation, Ferring Pharmaceuticals, Gilead/Galapagos, High5ImmunoTV, Janssen Pharmaceuticals, MSD, Pfizer, Takeda, Tillotts Pharma, and Vifor Pharma; and payment for manuscript preparation from the Falk Foundation, Takeda, Thieme Medical Publishers, and UNI-MED Verlag. Roblin X has served as an advisory board member, consultant, or speaker for AbbVie, Amgen, Biogen, Celltrion, Ferring Pharmaceuticals, Galapagos NV, Janssen Pharmaceuticals, MSD, Pfizer, Sandoz, and Takeda. Takatori Y and Kaise T are employees of Gilead Sciences K.K. and are shareholders of Gilead Sciences, Inc. Oortwijn A is an employee and shareholder of Galapagos NV. Jamoul C is a contractor for Galapagos NV. Hibi T has received lecture fees from Aspen Japan K.K., Janssen Pharmaceuticals, JIMRO, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co., Ltd., Pfizer, and Takeda; research grants from AbbVie GK, Activaid, Alfresa Pharma, Bristol Myers Squibb, Eli Lilly Japan K.K., Ferring Pharmaceuticals, Gilead Sciences, Inc., Janssen Pharmaceutical K.K., JMDC Inc., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Japan Inc., and Takeda; scholarship contributions from Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., and Zeria Pharmaceutical Co., Ltd.; and study group sponsorship from AbbVie GK, EA Pharma Co., Ltd., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Otsuka Holdings, and Zeria Pharmaceutical Co., Ltd.

Hibi T is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Data Availability Statement

Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae and reflecting non conflict of interest. The request proposal must also include a statistician. Approval of such requests is at Gilead Science’s discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datarequest@gilead.com.

Author Contributions

Conceptualization: Kobayashi T, Kaise T, Takatori Y, Hibi T. Data curation: Kobayashi T, Dignass A, Roblin X, Hibi T. Formal analysis: Kobayashi T, Kaise T, Takatori Y, Oortwijn A, Jamoul C, Hibi T. Funding acquisition: Kaise T, Takatori Y. Writing - original draft: all authors. Writing - review & editing: all authors. Approval of final manuscript: all authors.

Additional contribution

The authors are grateful to Yasushi Fujitani (formerly of Gilead Sciences K.K.) for his contributions to the study and drafting of the manuscript.

Supplementary Material

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Table 1.

Total CS Dose Exposure in mg From Maintenance Baseline to Week 58 in the Filgotinib 200 mg Group in Total and by Presence or Absence of CS-Free Remission in Patients Treated with CS at Maintenance Baseline

ir-2024-00007-Supplementary-Table-1.pdf

Table 1.

Induction Baseline Characteristics of Patients Treated with CS at Maintenance Baseline in the Filgotinib 200 mg and Filgotinib 100 mg Groups, Overall and by Presence or Absence of CS-Free Remission

Induction baseline characteristic	Filgotinib 200 mg			Filgotinib 100 mg
Induction baseline characteristic	Total (n = 92)	CS-free remission^a (n = 25)	No CS-free remission^b (n = 67)	Total (n = 81)	CS-free remission^a (n = 11)	No CS-free remission^b (n = 70)
Age (yr), mean ± SD	43.2 ± 14.4	42.0 ± 16.1	43.6 ± 13.8	41.9 ± 12.8	39.2 ± 9.7	42.4 ± 13.2
Sex
Female	53 (57.6)	19 (76.0)	34 (50.7)	38 (46.9)	6 (54.5)	32 (45.7)
Male	39 (42.4)	6 (24.0)	33 (49.3)	43 (53.1)	5 (45.5)	38 (54.3)
BMI
< 18.5 kg/m²	10 (10.9)	1 (4.0)	9 (13.4)	7 (8.6)	2 (18.2)	5 (7.1)
18.5 to < 25.0 kg/m²	45 (48.9)	14 (56.0)	31 (46.3)	44 (54.3)	5 (45.5)	39 (55.7)
25.0 to < 30.0 kg/m²	25 (27.2)	6 (24.0)	19 (28.4)	19 (23.5)	4 (36.4)	15 (21.4)
≥ 30.0 kg/m²	12 (13.0)	4 (16.0)	8 (11.9)	11 (13.6)	0	11 (15.7)
Smoking status
Current	8 (8.7)	5 (20.0)	3 (4.5)	5 (6.2)	1 (9.1)	4 (5.7)
Former	26 (28.3)	3 (12.0)	23 (34.3)	24 (29.6)	3 (27.3)	21 (30.0)
Never	58 (63.0)	17 (68.0)	41 (61.2)	52 (64.2)	7 (63.6)	45 (64.3)
History of pancolitis	47 (51.1)	13 (52.0)	34 (50.7)	46 (56.8)	7 (63.6)	39 (55.7)
Duration of UC
< 1 yr	5 (5.4)	3 (12.0)	2 (3.0)	9 (11.1)	3 (27.3)	6 (8.6)
1 to < 3 yr	23 (25.0)	5 (20.0)	18 (26.9)	14 (17.3)	2 (18.2)	12 (17.1)
3 to < 7 yr	27 (29.3)	6 (24.0)	21 (31.3)	21 (25.9)	3 (27.3)	18 (25.7)
≥ 7 yr	37 (40.2)	11 (44.0)	26 (38.8)	37 (45.7)	3 (27.3)	34 (48.6)
Fecal calprotectin level^c
≤ 500.0 µg/g	19 (20.7)	6 (24.0)	13 (19.4)	22 (27.2)	4 (36.4)	18 (25.7)
> 500.0 to 1,320.5 µg/g	16 (17.4)	2 (8.0)	14 (20.9)	14 (17.3)	2 (18.2)	12 (17.1)
> 1,320.5 to 2,658.0 µg/g	23 (25.0)	4 (16.0)	19 (28.4)	24 (29.6)	1 (9.1)	23 (32.9)
> 2,658.0 µg/g	33 (35.9)	12 (48.0)	21 (31.3)	21 (25.9)	4 (36.4)	17 (24.3)
Missing	1 (1.1)	1 (4.0)	0	0	0	0
CRP level^c
≤ 1.690 mg/L	29 (31.5)	4 (16.0)	25 (37.3)	23 (28.4)	4 (36.4)	19 (27.1)
> 1.690 to 4.415 mg/L	20 (21.7)	9 (36.0)	11 (16.4)	22 (27.2)	4 (36.4)	18 (25.7)
> 4.415 to 11.550 mg/L	25 (27.2)	6 (24.0)	19 (28.4)	21 (25.9)	1 (9.1)	20 (28.6)
> 11.550 mg/L	18 (19.6)	6 (24.0)	12 (17.9)	15 (18.5)	2 (18.2)	13 (18.6)
MCS
≤8	26 (28.3)	9 (36.0)	17 (25.4)	24 (29.6)	4 (36.4)	20 (28.6)
≥9	66 (71.7)	16 (64.0)	50 (74.6)	57 (70.4)	7 (63.6)	50 (71.4)
MES
2	33 (35.9)	16 (64.0)	17 (25.4)	23 (28.4)	6 (54.5)	17 (24.3)
3	59 (64.1)	9 (36.0)	50 (74.6)	58 (71.6)	5 (45.5)	53 (75.7)
Prior use of biologics	49 (53.3)	7 (28.0)	42 (62.7)	40 (49.4)	3 (27.3)	37 (52.9)
Concomitant oral, systemically absorbed CS
Yes	77 (83.7)	21 (84.0)	56 (83.6)	74 (91.4)	10 (90.9)	64 (91.4)
Oral, systemically absorbed CS dose
> 0 to 10 mg/day	28 (30.4)	8 (32.0)	20 (29.9)	27 (33.3)	4 (36.4)	23 (32.9)
> 10 to 20 mg/day	35 (38.0)	7 (28.0)	28 (41.8)	25 (30.9)	2 (18.2)	23 (32.9)
> 20 mg/day	14 (15.2)	6 (24.0)	8 (11.9)	22 (27.2)	4 (36.4)	18 (25.7)
No	15 (16.3)	4 (16.0)	11 (16.4)	7 (8.6)	1 (9.1)	6 (8.6)
Concomitant immunomodulators	21 (22.8)	7 (28.0)	14 (20.9)	16 (19.8)	1 (9.1)	15 (21.4)
Concomitant aminosalicylates	73 (79.3)	22 (88.0)	51 (76.1)	58 (71.6)	9 (81.8)	49 (70.0)

Values are presented as number (%) unless otherwise indicated.

^a Patients who achieved clinical remission at week 58 without using CS to treat UC over a continuous period of at least 6 months.

^b Patients who did not achieve clinical remission at week 58 without using CS to treat UC over a continuous period of at least 6 months.

^c Ranges represent division of the data set by the 3 quartiles.

CS, corticosteroid; SD, standard deviation; BMI, body mass index; UC, ulcerative colitis; CRP, C-reactive protein; MCS, Mayo Clinic Score; MES, Mayo Clinic Endoscopic Subscore.

Table 2.

Associations Between CS-Free Clinical Remission (Dependent Variable) and Induction Baseline Characteristics by Treatment Group in Patients Treated with CS at Maintenance Baseline

Induction baseline characteristic	Filgotinib 200 mg (n = 92)		Filgotinib 100 mg (n = 81)
Induction baseline characteristic	OR (95% CI)	P-value	OR (95% CI)	P-value
Age	0.993 (0.960 to 1.025)	0.649	0.980 (0.928 to 1.031)	0.442
Male sex (ref: female)	0.325 (0.116 to 0.916)	0.034^a	0.702 (0.196 to 2.515)	0.587
BMI (ref: 18.5 to < 25.0 kg/m²)		0.574		0.610
< 18.5 kg/m²	0.246 (0.028 to 2.134)		3.120 (0.473 to 20.564)
25.0 to < 30.0 kg/m²	0.699 (0.230 to 2.130)		2.080 (0.491 to 8.808)
≥ 30.0 kg/m²	1.107 (0.285 to 4.297)		0.000 (0.000 to NA)^b
Smoking status (ref: current)		0.028^a		0.906
Former	0.078 (0.012 to 0.508)		0.571 (0.047 to 6.983)
Never	0.249 (0.053 to 1.159)		0.622 (0.060 to 6.405)
History of pancolitis (ref: no history)	1.078 (0.421 to 2.756)	0.876	1.346 (0.361 to 5.026)	0.658
Duration of UC (ref: < 1 yr)		0.374		0.320
1 to < 3 yr	0.185 (0.024 to 1.432)		0.333 (0.043 to 2.564)
3 to < 7 yr	0.190 (0.026 to 1.416)		0.333 (0.053 to 2.115)
≥ 7 yr	0.282 (0.041 to 1.930)		0.176 (0.029 to 1.090)
Fecal calprotectin level (ref: ≤ 500.0 µg/g)^c		0.236		0.508
> 500.0 to 1,320.5 µg/g	0.310 (0.053 to 1.816)		0.750 (0.118 to 4.760)
> 1,320.5 to 2,658.0 µg/g	0.456 (0.107 to 1.942)		0.196 (0.020 to 1.905)
> 2,658.0 µg/g	1.238 (0.373 to 4.109)		1.059 (0.228 to 4.921)
CRP level (ref: ≤ 1.690 mg/L)^c		0.118		0.610
> 1.690 to 4.415 mg/L	5.114 (1.293 to 20.221)		1.056 (0.229 to 4.867)
> 4.415 to 11.550 mg/L	1.974 (0.487 to 7.994)		0.238 (0.024 to 2.320)
> 11.550 mg/L	3.125 (0.740 to 13.193)		0.731 (0.116 to 4.593)
MCS ≤ 8 (ref: ≥ 9)	1.654 (0.618 to 4.429)	0.316	1.429 (0.377 to 5.420)	0.600
MES of 2 (ref: 3)	5.229 (1.953 to 13.997)	0.001^a	3.741 (1.013 to 13.817)	0.048^a
Biologic-experienced (ref: biologic-naive)	0.231 (0.085 to 0.632)	0.004^a	0.334 (0.082 to 1.366)	0.127
Concomitant oral, systemically absorbed CS use (ref: nonuse)	1.031 (0.296 to 3.597)	0.962	0.938 (0.102 to 8.627)	0.955
Oral, systemically absorbed CS dose (ref: > 0 to 10 mg/day)		0.276		0.590
> 10 to 20 mg/day	0.625 (0.195 to 2.005)		0.500 (0.083 to 3.004)
> 20 mg/day	1.875 (0.491 to 7.153)		1.278 (0.280 to 5.825)
Concomitant immunomodulators (ref: nonuse)	1.472 (0.514 to 4.220)	0.472	0.367 (0.043 to 3.096)	0.357
Concomitant aminosalicylates (ref: nonuse)	2.301 (0.608 to 8.704)	0.220	1.929 (0.383 to 9.699)	0.425

P-values are based on the Wald chi-square test using the type 3 analysis of effects in logistic regression.

^a Statistical significance, P<0.05.

^b OR of 0 results from 0 counts owing to small sample size.

^c Ranges represent division of the data set by the 3 quartiles.

CS, corticosteroid; OR, odds ratio; CI, confidence interval; ref, reference; BMI, body mass index; NA, not applicable; UC, ulcerative colitis; CRP, C-reactive protein; MCS, Mayo Clinic Score; MES, Mayo Clinic Endoscopic Subscore.

Table 3.

Univariate Analysis of Associations Between Induction Baseline Characteristics and Total CS Dose Exposure from Maintenance Baseline in Patients in the Filgotinib 200 mg Group Treated with CS at Maintenance Baseline (n=92)

Induction baseline characteristic	No.	Total CS dose exposure (mg), mean (95% CI)	Difference in mean (95% CI)	P-value	Type 3 overall P-value
Overall	92	213.7 (161.37 to 266.04)
Sex
Female (ref)	53	178.1 (127.45 to 228.72)	84.0 (−19.61 to 187.65)	0.116
Male	39	262.1 (158.29 to 365.93)
BMI
< 18.5 kg/m²	10	319.9 (95.99 to 543.91)	105.5 (−68.11 to 279.18)	0.237	0.447
18.5 to < 25.0 kg/m² (ref)	45	214.4 (125.49 to 303.35)
25.0 to < 30.0 kg/m²	25	197.9 (125.47 to 270.33)	−16.5 (−140.42 to 107.38)	0.794
≥ 30.0 kg/m²	12	155.4 (75.17 to 235.66)	−59.0 (−220.37 to 102.37)	0.476
Smoking status
Current	8	108.1 (23.46 to 192.79)	−156.3 (−338.47 to 25.80)	0.096	0.035^a
Former	26	133.0 (74.55 to 191.37)	−131.5 (−245.48 to −17.52)	0.026^a
Never (ref)	58	264.5 (188.09 to 340.83)
History of pancolitis
Yes	47	184.4 (121.65 to 247.16)	−66.5 (−171.76 to 38.72)	0.219
No (ref)	42	250.9 (160.37 to 341.48)
Unknown	3	151.7 (−500.90 to 804.24)
Duration of UC
< 3 yr (ref)	28	180.8 (108.97 to 252.53)
3 to < 7 yr	27	238.7 (128.86 to 348.62)	58.0 (−76.53 to 192.51)	0.400	0.685
≥ 7 yr	37	220.4 (126.87 to 313.88)	39.6 (−85.30 to 164.54)	0.536
Fecal calprotectin level^b
≤ 500.0 µg/g (ref)	19	280.5 (141.45 to 419.60)
> 500.0 to 1,320.5 µg/g	16	195.5 (−10.42 to 401.52)	−85.0 (−254.13 to 84.17)	0.328	0.538
> 1,320.5 to 2,658.0 µg/g	23	167.8 (114.83 to 220.82)	−112.7 (−267.24 to 41.84)	0.157
> 2,658.0 µg/g	33	222.3 (144.02 to 300.49)	−58.3 (−201.83 to 85.29)	0.428
Missing	1	7.5 (NA to NA)
CRP level^b
≤ 1.690 mg/L (ref)	29	283.4 (151.74 to 415.07)
> 1.690 to 4.415 mg/L	20	221.1 (107.29 to 334.96)	−62.3 (−205.32 to 80.76)	0.396	0.243
> 4.415 to 11.550 mg/L	25	149.1 (87.29 to 210.87)	−134.3 (−268.63 to −0.02)	0.053
> 11.550 mg/L	18	182.9 (95.01 to 270.82)	−100.5 (−248.16 to 47.18)	0.186
MCS
≤8	26	202.8 (81.19 to 324.37)	−15.2 (−130.51 to 100.05)	0.796
≥ 9 (ref)	66	218.0 (160.62 to 275.39)
MES
2	33	246.3 (141.53 to 351.12)	50.9 (−56.88 to 158.62)	0.357
3 (ref)	59	195.5 (136.57 to 254.35)
Rectal Bleeding Subscore < 2
Yes	33	274.4 (154.39 to 394.47)	94.7 (−11.79 to 201.18)	0.085
No (ref)	59	179.7 (131.90 to 227.58)
Stool Frequency Subscore ≤ 2
Yes	40	190.7 (103.75 to 277.74)	−40.6 (−145.03 to 63.79)	0.448
No (ref)	52	231.4 (165.11 to 297.62)
Biologic-naive
Yes	44	176.0 (117.78 to 234.31)	−72.2 (−175.05 to 30.70)	0.172
No (ref)	48	248.2 (162.33 to 334.12)
Prior use of TNF-α antagonist, induction study B
Yes	45	261.1 (170.65 to 351.56)	174.9 (−123.65 to 473.36)	0.257
No (ref)	4	86.2 (−31.29 to 203.79)
Prior failure of TNF-α antagonist, induction study B
Yes	43	268.0 (174.03 to 362.00)	173.0 (−74.90 to 420.94)	0.178
No (ref)	6	95.0 (−1.87 to 191.87)
Prior use of vedolizumab, induction study B
Yes	29	255.5 (130.44 to 380.51)	21.2 (−147.33 to 189.68)	0.807
No (ref)	20	234.3 (122.39 to 346.21)
Prior failure of vedolizumab, induction study B
Yes	24	288.1 (139.50 to 436.64)	80.8 (−83.32 to 244.99)	0.339
No (ref)	25	207.2 (115.33 to 299.15)
Prior use of TNF-α antagonist and vedolizumab, induction study B
Yes	26	278.6 (141.36 to 415.85)	67.7 (−97.23 to 232.61)	0.425
No (ref)	23	210.9 (110.98 to 310.84)
Concomitant aminosalicylates
Yes	73	186.2 (141.87 to 230.58)	−133.1 (−258.34 to −7.76)	0.040^a
No (ref)	19	319.3 (124.39 to 514.16)

P-values are based on the Wald chi-square test using the type 3 analysis of effects in linear regression.

^a Statistical significance, P<0.05.

^b Ranges represent division of the data set by the 3 quartiles.

CS, corticosteroid; CI, confidence interval; BMI, body mass index; UC, ulcerative colitis; NA, not applicable; CRP, C-reactive protein; MCS, Mayo Clinic Score; MES, Mayo Clinic Endoscopic Subscore; ref, reference; TNF, tumor necrosis factor.

REFERENCES

1. Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 2022;16:2–17.Article PubMed PDF
2. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019;114:384–413.Article PubMed
3. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68(Suppl 3): s1–s106.Article PubMed PMC
4. Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021;397:2372–2384.Article PubMed
5. Loftus EV, Vermeire S, Feagan BG, et al. Corticosteroid-sparing effects of filgotinib in moderately to severely active ulcerative colitis: data from the phase 2b/3 SELECTION Study. J Crohns Colitis 2023;17:211–220.Article PubMed PMC PDF
6. Schreiber S, Danese S, Dignass A, et al. Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: international Delphi consensus recommendations. J Crohns Colitis 2024;18:91–105.Article PubMed PMC PDF
7. Danese S, Ferrante M, Feagan BG, et al. Rapid and sustained symptom relief in patients with ulcerative colitis treated with filgotinib: data from the phase 2b/3 SELECTION Trial. Am J Gastroenterol 2023;118:138–147.Article PubMed PMC
8. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–1201.Article PubMed
9. Lee SD, Allegretti JR, Steinwurz F, et al. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore. BMC Gastroenterol 2023;23:34.Article PubMed PMC PDF
10. Barreiro-de Acosta M, Vallejo N, de la Iglesia D, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study. J Crohns Colitis 2016;10:13–19.Article PubMed
11. Watanabe K, Peyrin-Biroulet L, Danese S, et al. Impact of concomitant thiopurine on the efficacy and safety of filgotinib in patients with ulcerative colitis: post hoc analysis of the phase 2b/3 SELECTION Study. J Crohns Colitis 2024;18:801–811.Article PubMed PMC PDF
12. Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. Therap Adv Gastroenterol 2020;Apr 28 [Epub]. https://doi.org/10.1177/1756284820915043.Article PubMed
13. To N, Gracie DJ, Ford AC. Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn’s disease. Aliment Pharmacol Ther 2016;43:549–561.Article PubMed PDF
14. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008;23:1213–1221.Article PubMed PDF
15. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989;34:1841–1854.Article PubMed PDF
16. Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J (Clin Res Ed) 1982;284:706.Article PubMed PMC
17. van der Heide F, Dijkstra A, Weersma RK, et al. Effects of active and passive smoking on disease course of Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2009;15:1199–1207.Article PubMed
18. Lunney PC, Kariyawasam VC, Wang RR, et al. Smoking prevalence and its influence on disease course and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther 2015;42:61–70.Article PubMed
19. Blackwell J, Saxena S, Alexakis C, et al. The impact of smoking and smoking cessation on disease outcomes in ulcerative colitis: a nationwide population-based study. Aliment Pharmacol Ther 2019;50:556–567.Article PubMed PDF
20. Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994;330:811–815.Article PubMed
21. Thomas GA, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995;332:988–992.Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

In which patients with ulcerative colitis would filgotinib be effective?
Jihye Park
Intestinal Research.2025; 23(1): 1. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study

Intest Res. 2025;23(1):65-75. Published online June 14, 2024

DOI: https://doi.org/10.5217/ir.2024.00007

XML Download

Figure

Related articles

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study

Graphical abstract

Graphical abstract

Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study

Induction baseline characteristic	Filgotinib 200 mg			Filgotinib 100 mg
Induction baseline characteristic	Total (n = 92)	CS-free remission^a (n = 25)	No CS-free remission^b (n = 67)	Total (n = 81)	CS-free remission^a (n = 11)	No CS-free remission^b (n = 70)
Age (yr), mean ± SD	43.2 ± 14.4	42.0 ± 16.1	43.6 ± 13.8	41.9 ± 12.8	39.2 ± 9.7	42.4 ± 13.2
Sex
Female	53 (57.6)	19 (76.0)	34 (50.7)	38 (46.9)	6 (54.5)	32 (45.7)
Male	39 (42.4)	6 (24.0)	33 (49.3)	43 (53.1)	5 (45.5)	38 (54.3)
BMI
< 18.5 kg/m²	10 (10.9)	1 (4.0)	9 (13.4)	7 (8.6)	2 (18.2)	5 (7.1)
18.5 to < 25.0 kg/m²	45 (48.9)	14 (56.0)	31 (46.3)	44 (54.3)	5 (45.5)	39 (55.7)
25.0 to < 30.0 kg/m²	25 (27.2)	6 (24.0)	19 (28.4)	19 (23.5)	4 (36.4)	15 (21.4)
≥ 30.0 kg/m²	12 (13.0)	4 (16.0)	8 (11.9)	11 (13.6)	0	11 (15.7)
Smoking status
Current	8 (8.7)	5 (20.0)	3 (4.5)	5 (6.2)	1 (9.1)	4 (5.7)
Former	26 (28.3)	3 (12.0)	23 (34.3)	24 (29.6)	3 (27.3)	21 (30.0)
Never	58 (63.0)	17 (68.0)	41 (61.2)	52 (64.2)	7 (63.6)	45 (64.3)
History of pancolitis	47 (51.1)	13 (52.0)	34 (50.7)	46 (56.8)	7 (63.6)	39 (55.7)
Duration of UC
< 1 yr	5 (5.4)	3 (12.0)	2 (3.0)	9 (11.1)	3 (27.3)	6 (8.6)
1 to < 3 yr	23 (25.0)	5 (20.0)	18 (26.9)	14 (17.3)	2 (18.2)	12 (17.1)
3 to < 7 yr	27 (29.3)	6 (24.0)	21 (31.3)	21 (25.9)	3 (27.3)	18 (25.7)
≥ 7 yr	37 (40.2)	11 (44.0)	26 (38.8)	37 (45.7)	3 (27.3)	34 (48.6)
Fecal calprotectin level^c
≤ 500.0 µg/g	19 (20.7)	6 (24.0)	13 (19.4)	22 (27.2)	4 (36.4)	18 (25.7)
> 500.0 to 1,320.5 µg/g	16 (17.4)	2 (8.0)	14 (20.9)	14 (17.3)	2 (18.2)	12 (17.1)
> 1,320.5 to 2,658.0 µg/g	23 (25.0)	4 (16.0)	19 (28.4)	24 (29.6)	1 (9.1)	23 (32.9)
> 2,658.0 µg/g	33 (35.9)	12 (48.0)	21 (31.3)	21 (25.9)	4 (36.4)	17 (24.3)
Missing	1 (1.1)	1 (4.0)	0	0	0	0
CRP level^c
≤ 1.690 mg/L	29 (31.5)	4 (16.0)	25 (37.3)	23 (28.4)	4 (36.4)	19 (27.1)
> 1.690 to 4.415 mg/L	20 (21.7)	9 (36.0)	11 (16.4)	22 (27.2)	4 (36.4)	18 (25.7)
> 4.415 to 11.550 mg/L	25 (27.2)	6 (24.0)	19 (28.4)	21 (25.9)	1 (9.1)	20 (28.6)
> 11.550 mg/L	18 (19.6)	6 (24.0)	12 (17.9)	15 (18.5)	2 (18.2)	13 (18.6)
MCS
≤8	26 (28.3)	9 (36.0)	17 (25.4)	24 (29.6)	4 (36.4)	20 (28.6)
≥9	66 (71.7)	16 (64.0)	50 (74.6)	57 (70.4)	7 (63.6)	50 (71.4)
MES
2	33 (35.9)	16 (64.0)	17 (25.4)	23 (28.4)	6 (54.5)	17 (24.3)
3	59 (64.1)	9 (36.0)	50 (74.6)	58 (71.6)	5 (45.5)	53 (75.7)
Prior use of biologics	49 (53.3)	7 (28.0)	42 (62.7)	40 (49.4)	3 (27.3)	37 (52.9)
Concomitant oral, systemically absorbed CS
Yes	77 (83.7)	21 (84.0)	56 (83.6)	74 (91.4)	10 (90.9)	64 (91.4)
Oral, systemically absorbed CS dose
> 0 to 10 mg/day	28 (30.4)	8 (32.0)	20 (29.9)	27 (33.3)	4 (36.4)	23 (32.9)
> 10 to 20 mg/day	35 (38.0)	7 (28.0)	28 (41.8)	25 (30.9)	2 (18.2)	23 (32.9)
> 20 mg/day	14 (15.2)	6 (24.0)	8 (11.9)	22 (27.2)	4 (36.4)	18 (25.7)
No	15 (16.3)	4 (16.0)	11 (16.4)	7 (8.6)	1 (9.1)	6 (8.6)
Concomitant immunomodulators	21 (22.8)	7 (28.0)	14 (20.9)	16 (19.8)	1 (9.1)	15 (21.4)
Concomitant aminosalicylates	73 (79.3)	22 (88.0)	51 (76.1)	58 (71.6)	9 (81.8)	49 (70.0)

Induction baseline characteristic	Filgotinib 200 mg (n = 92)		Filgotinib 100 mg (n = 81)
Induction baseline characteristic	OR (95% CI)	P-value	OR (95% CI)	P-value
Age	0.993 (0.960 to 1.025)	0.649	0.980 (0.928 to 1.031)	0.442
Male sex (ref: female)	0.325 (0.116 to 0.916)	0.034^a	0.702 (0.196 to 2.515)	0.587
BMI (ref: 18.5 to < 25.0 kg/m²)		0.574		0.610
< 18.5 kg/m²	0.246 (0.028 to 2.134)		3.120 (0.473 to 20.564)
25.0 to < 30.0 kg/m²	0.699 (0.230 to 2.130)		2.080 (0.491 to 8.808)
≥ 30.0 kg/m²	1.107 (0.285 to 4.297)		0.000 (0.000 to NA)^b
Smoking status (ref: current)		0.028^a		0.906
Former	0.078 (0.012 to 0.508)		0.571 (0.047 to 6.983)
Never	0.249 (0.053 to 1.159)		0.622 (0.060 to 6.405)
History of pancolitis (ref: no history)	1.078 (0.421 to 2.756)	0.876	1.346 (0.361 to 5.026)	0.658
Duration of UC (ref: < 1 yr)		0.374		0.320
1 to < 3 yr	0.185 (0.024 to 1.432)		0.333 (0.043 to 2.564)
3 to < 7 yr	0.190 (0.026 to 1.416)		0.333 (0.053 to 2.115)
≥ 7 yr	0.282 (0.041 to 1.930)		0.176 (0.029 to 1.090)
Fecal calprotectin level (ref: ≤ 500.0 µg/g)^c		0.236		0.508
> 500.0 to 1,320.5 µg/g	0.310 (0.053 to 1.816)		0.750 (0.118 to 4.760)
> 1,320.5 to 2,658.0 µg/g	0.456 (0.107 to 1.942)		0.196 (0.020 to 1.905)
> 2,658.0 µg/g	1.238 (0.373 to 4.109)		1.059 (0.228 to 4.921)
CRP level (ref: ≤ 1.690 mg/L)^c		0.118		0.610
> 1.690 to 4.415 mg/L	5.114 (1.293 to 20.221)		1.056 (0.229 to 4.867)
> 4.415 to 11.550 mg/L	1.974 (0.487 to 7.994)		0.238 (0.024 to 2.320)
> 11.550 mg/L	3.125 (0.740 to 13.193)		0.731 (0.116 to 4.593)
MCS ≤ 8 (ref: ≥ 9)	1.654 (0.618 to 4.429)	0.316	1.429 (0.377 to 5.420)	0.600
MES of 2 (ref: 3)	5.229 (1.953 to 13.997)	0.001^a	3.741 (1.013 to 13.817)	0.048^a
Biologic-experienced (ref: biologic-naive)	0.231 (0.085 to 0.632)	0.004^a	0.334 (0.082 to 1.366)	0.127
Concomitant oral, systemically absorbed CS use (ref: nonuse)	1.031 (0.296 to 3.597)	0.962	0.938 (0.102 to 8.627)	0.955
Oral, systemically absorbed CS dose (ref: > 0 to 10 mg/day)		0.276		0.590
> 10 to 20 mg/day	0.625 (0.195 to 2.005)		0.500 (0.083 to 3.004)
> 20 mg/day	1.875 (0.491 to 7.153)		1.278 (0.280 to 5.825)
Concomitant immunomodulators (ref: nonuse)	1.472 (0.514 to 4.220)	0.472	0.367 (0.043 to 3.096)	0.357
Concomitant aminosalicylates (ref: nonuse)	2.301 (0.608 to 8.704)	0.220	1.929 (0.383 to 9.699)	0.425

Induction baseline characteristic	No.	Total CS dose exposure (mg), mean (95% CI)	Difference in mean (95% CI)	P-value	Type 3 overall P-value
Overall	92	213.7 (161.37 to 266.04)
Sex
Female (ref)	53	178.1 (127.45 to 228.72)	84.0 (−19.61 to 187.65)	0.116
Male	39	262.1 (158.29 to 365.93)
BMI
< 18.5 kg/m²	10	319.9 (95.99 to 543.91)	105.5 (−68.11 to 279.18)	0.237	0.447
18.5 to < 25.0 kg/m² (ref)	45	214.4 (125.49 to 303.35)
25.0 to < 30.0 kg/m²	25	197.9 (125.47 to 270.33)	−16.5 (−140.42 to 107.38)	0.794
≥ 30.0 kg/m²	12	155.4 (75.17 to 235.66)	−59.0 (−220.37 to 102.37)	0.476
Smoking status
Current	8	108.1 (23.46 to 192.79)	−156.3 (−338.47 to 25.80)	0.096	0.035^a
Former	26	133.0 (74.55 to 191.37)	−131.5 (−245.48 to −17.52)	0.026^a
Never (ref)	58	264.5 (188.09 to 340.83)
History of pancolitis
Yes	47	184.4 (121.65 to 247.16)	−66.5 (−171.76 to 38.72)	0.219
No (ref)	42	250.9 (160.37 to 341.48)
Unknown	3	151.7 (−500.90 to 804.24)
Duration of UC
< 3 yr (ref)	28	180.8 (108.97 to 252.53)
3 to < 7 yr	27	238.7 (128.86 to 348.62)	58.0 (−76.53 to 192.51)	0.400	0.685
≥ 7 yr	37	220.4 (126.87 to 313.88)	39.6 (−85.30 to 164.54)	0.536
Fecal calprotectin level^b
≤ 500.0 µg/g (ref)	19	280.5 (141.45 to 419.60)
> 500.0 to 1,320.5 µg/g	16	195.5 (−10.42 to 401.52)	−85.0 (−254.13 to 84.17)	0.328	0.538
> 1,320.5 to 2,658.0 µg/g	23	167.8 (114.83 to 220.82)	−112.7 (−267.24 to 41.84)	0.157
> 2,658.0 µg/g	33	222.3 (144.02 to 300.49)	−58.3 (−201.83 to 85.29)	0.428
Missing	1	7.5 (NA to NA)
CRP level^b
≤ 1.690 mg/L (ref)	29	283.4 (151.74 to 415.07)
> 1.690 to 4.415 mg/L	20	221.1 (107.29 to 334.96)	−62.3 (−205.32 to 80.76)	0.396	0.243
> 4.415 to 11.550 mg/L	25	149.1 (87.29 to 210.87)	−134.3 (−268.63 to −0.02)	0.053
> 11.550 mg/L	18	182.9 (95.01 to 270.82)	−100.5 (−248.16 to 47.18)	0.186
MCS
≤8	26	202.8 (81.19 to 324.37)	−15.2 (−130.51 to 100.05)	0.796
≥ 9 (ref)	66	218.0 (160.62 to 275.39)
MES
2	33	246.3 (141.53 to 351.12)	50.9 (−56.88 to 158.62)	0.357
3 (ref)	59	195.5 (136.57 to 254.35)
Rectal Bleeding Subscore < 2
Yes	33	274.4 (154.39 to 394.47)	94.7 (−11.79 to 201.18)	0.085
No (ref)	59	179.7 (131.90 to 227.58)
Stool Frequency Subscore ≤ 2
Yes	40	190.7 (103.75 to 277.74)	−40.6 (−145.03 to 63.79)	0.448
No (ref)	52	231.4 (165.11 to 297.62)
Biologic-naive
Yes	44	176.0 (117.78 to 234.31)	−72.2 (−175.05 to 30.70)	0.172
No (ref)	48	248.2 (162.33 to 334.12)
Prior use of TNF-α antagonist, induction study B
Yes	45	261.1 (170.65 to 351.56)	174.9 (−123.65 to 473.36)	0.257
No (ref)	4	86.2 (−31.29 to 203.79)
Prior failure of TNF-α antagonist, induction study B
Yes	43	268.0 (174.03 to 362.00)	173.0 (−74.90 to 420.94)	0.178
No (ref)	6	95.0 (−1.87 to 191.87)
Prior use of vedolizumab, induction study B
Yes	29	255.5 (130.44 to 380.51)	21.2 (−147.33 to 189.68)	0.807
No (ref)	20	234.3 (122.39 to 346.21)
Prior failure of vedolizumab, induction study B
Yes	24	288.1 (139.50 to 436.64)	80.8 (−83.32 to 244.99)	0.339
No (ref)	25	207.2 (115.33 to 299.15)
Prior use of TNF-α antagonist and vedolizumab, induction study B
Yes	26	278.6 (141.36 to 415.85)	67.7 (−97.23 to 232.61)	0.425
No (ref)	23	210.9 (110.98 to 310.84)
Concomitant aminosalicylates
Yes	73	186.2 (141.87 to 230.58)	−133.1 (−258.34 to −7.76)	0.040^a
No (ref)	19	319.3 (124.39 to 514.16)

Table 1. Induction Baseline Characteristics of Patients Treated with CS at Maintenance Baseline in the Filgotinib 200 mg and Filgotinib 100 mg Groups, Overall and by Presence or Absence of CS-Free Remission

Values are presented as number (%) unless otherwise indicated.

Patients who achieved clinical remission at week 58 without using CS to treat UC over a continuous period of at least 6 months.

Patients who did not achieve clinical remission at week 58 without using CS to treat UC over a continuous period of at least 6 months.

Ranges represent division of the data set by the 3 quartiles.

CS, corticosteroid; SD, standard deviation; BMI, body mass index; UC, ulcerative colitis; CRP, C-reactive protein; MCS, Mayo Clinic Score; MES, Mayo Clinic Endoscopic Subscore.

Table 2. Associations Between CS-Free Clinical Remission (Dependent Variable) and Induction Baseline Characteristics by Treatment Group in Patients Treated with CS at Maintenance Baseline

P-values are based on the Wald chi-square test using the type 3 analysis of effects in logistic regression.

Statistical significance, P<0.05.

OR of 0 results from 0 counts owing to small sample size.

Ranges represent division of the data set by the 3 quartiles.

Table 3. Univariate Analysis of Associations Between Induction Baseline Characteristics and Total CS Dose Exposure from Maintenance Baseline in Patients in the Filgotinib 200 mg Group Treated with CS at Maintenance Baseline (n=92)

P-values are based on the Wald chi-square test using the type 3 analysis of effects in linear regression.